Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H7Z7

UPID:
PGES2_HUMAN

ALTERNATIVE NAMES:
Membrane-associated prostaglandin E synthase-2; Microsomal prostaglandin E synthase 2; Prostaglandin-H(2) E-isomerase

ALTERNATIVE UPACC:
Q9H7Z7; Q53EW9; Q5SYV6; Q96GI0; Q96GL2

BACKGROUND:
The enzyme Prostaglandin E synthase 2, known for its alternative names such as Microsomal prostaglandin E synthase 2, is pivotal in prostaglandin biosynthesis. It catalyzes the transformation of PGH2 into PGE2 in vitro, and its interaction with GSH and heme suggests a multifaceted role in vivo, including the potential degradation of PGH2.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional nature of Prostaglandin E synthase 2 unveils promising pathways for therapeutic intervention, particularly in conditions where prostaglandin metabolism plays a key role.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.